Puma Biotech director sells 62K shares at $9.12

PBYI director Alessandra Cesano exercised options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

PUMA BIOTECHNOLOGY, INC. (PBYI) director Alessandra Cesano reported an option exercise and share sale on September 14, 2026. She exercised 50,000 stock options for common stock at an exercise price of $2.93 per share, receiving 50,000 common shares. On the same date, she sold 62,150 common shares at a weighted average price of $9.123 per share in multiple transactions within a $9.03–$9.20 range. The filing states these sales were made under a Rule 10b5-1(c) trading plan adopted on June 15, 2026, and the stock option reported as exercised is fully vested and expires on July 28, 2032.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Cesano Alessandra

Role Director

Sold 62,150 shs ($567K)

Approx. gross sale proceeds $567K

Approx. exercise cost $147K

Type	Security	Shares	Price	Value
Exercise	Stock Option F3	50,000	$0.00	$0.00
Exercise	Common Stock	50,000	$2.93	$147K
Sale	Common Stock F1, F2	62,150	$9.123	$567K

Holdings After Transaction: Stock Option — 50,000 contracts (Direct); Common Stock — 56,700 shares (Direct)

Footnotes (3)

1. F1. Adoption date of referenced 10b5-1(c) plan is: 06-15-2026
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.2, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. The Stock Option is fully vested.

Key Figures

Options Exercised: 50,000 shares Option Exercise Price: $2.93 per share Shares Sold: 62,150 shares +3 more

6 metrics

Options Exercised 50,000 shares Stock options for PBYI common stock exercised on September 14, 2026 at $2.93 per share

Option Exercise Price $2.93 per share Exercise price for 50,000 stock options converted into PBYI common stock

Shares Sold 62,150 shares PBYI common stock sold on September 14, 2026

Weighted Average Sale Price $9.123 per share Weighted average price for 62,150 PBYI shares sold, with trades between $9.03 and $9.20

Rule 10b5-1 Plan Adoption Date June 15, 2026 Adoption date of the trading plan governing the reported sales

Option Expiration Date July 28, 2032 Expiration date of the fully vested stock option that was exercised

Key Terms

Rule 10b5-1(c) plan, weighted average price, Stock Option

3 terms

Rule 10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 06-15-2026"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option financial

"The Stock Option is fully vested."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PUMA BIOTECHNOLOGY (PBYI) director Alessandra Cesano report on this Form 4?

She reported exercising 50,000 stock options at an exercise price of $2.93 per share and selling 62,150 common shares on September 14, 2026 under a pre-arranged Rule 10b5-1(c) trading plan.

How many PBYI shares did Alessandra Cesano sell and at what price range?

She sold 62,150 common shares of PBYI at a weighted average price of $9.123 per share, with individual trades executed in a price range from $9.03 to $9.20 per share.

What options did Alessandra Cesano exercise in PUMA BIOTECHNOLOGY (PBYI)?

She exercised 50,000 stock options for PBYI common stock at an exercise price of $2.93 per share. The filing notes that the stock option is fully vested and carries an expiration date of July 28, 2032.

Was the PBYI share sale by Alessandra Cesano under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made under a Rule 10b5-1(c) trading plan with an adoption date of June 15, 2026, indicating the trades were pre-arranged rather than opportunistic.

What is the weighted average sale price for Alessandra Cesano’s PBYI share sale?

The reported weighted average sale price for the 62,150 common shares sold is $9.123 per share. A footnote explains that individual trades occurred between $9.03 and $9.20 per share.

What is the expiration date of the PBYI stock options exercised by Alessandra Cesano?

The stock option exercised for 50,000 shares of PBYI common stock has an expiration date of July 28, 2032, and is described in the filing as fully vested at the time of exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 09:06 PM Accepted by SEC EDGAR 09/16/2026 - 09:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cesano Alessandra

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		M		50,000	A	$2.93	118,850	D
Common Stock	09/14/2026		S(1)		62,150	D	$9.123(2)	56,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.93	09/14/2026		M			50,000	(3)	07/28/2032	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 06-15-2026

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.2, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The Stock Option is fully vested.

	/s/ Chris Culotta as attorney-in-fact for Alessandra Cesano	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)